Original Article
Free Access
Significantly lower incidence of cancer among patients with Huntington disease
An apoptotic effect of an expanded polyglutamine tract?
First published: 20 November 2000
Cited by: 46
Abstract
BACKGROUND
The authors of this study have previously observed that cancer is rarely reported on the death certificates of patients with Huntington disease. This study was undertaken to investigate whether this disorder is associated with a lower incidence of cancer.
METHODS
A total of 694 patients with Huntington disease who had survived at least to age 45 years during the period 1943–1993, and 695 individuals at risk and at least age 55 years during the same period, were selected from the Danish Huntington Disease Registry. The occurrence of cancer was determined from the files of the Danish Cancer Registry and compared with national incidence rates for various categories of tumors.
RESULTS
The overall incidence of cancer was significantly lower among patients with Huntington disease, but not among their healthy relatives. The standardized incidence ratio for the Huntington patients was 0.6 with a 95% confidence interval of 0.5–0.8. The lower incidence was seen for cancers of all major tissues and organs except the buccal cavity and the pharynx.
CONCLUSIONS
The lower incidence of cancer among patients with Huntington disease seems to be related to intrinsic biologic factors. One explanation may be that the modified protein, huntingtin, encountered in Huntington disease protects against cancer by inducing or increasing the rate of naturally occurring programmed cell death in preneoplastic cells. Cancer 1999;86:1342–6. © 1999 American Cancer Society.
Citing Literature
Number of times cited: 46
- Andrea E Murmann, Quan Q Gao, William E Putzbach, Monal Patel, Elizabeth T Bartom, Calvin Y Law, Bryan Bridgeman, Siquan Chen, Kaylin M McMahon, C Shad Thaxton and Marcus E Peter, Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells, EMBO reports, 19, 3, (2018).
- Andrea E. Murmann, Jindan Yu, Puneet Opal and Marcus E. Peter, Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer, Trends in Cancer, 10.1016/j.trecan.2018.08.004, (2018).
- M. Gilling, E. Budtz‐Jørgensen, S.E. Boonen, D. Lildballe, A. Bojesen, J.M. Hertz and S.A. Sørensen, The Danish HD Registry—a nationwide family registry of HD families in Denmark, Clinical Genetics, 92, 3, (338-341), (2017).
- A. Robles Bayón and F. Gude Sampedro, Nueva observación de la protección relativa que las enfermedades neurodegenerativas y el cáncer se confieren entre sí, Neurología, (2017).
- Miles R. Bryan and Aaron B. Bowman, Manganese and the Insulin-IGF Signaling Network in Huntington’s Disease and Other Neurodegenerative Disorders, Neurotoxicity of Metals, 10.1007/978-3-319-60189-2_6, (113-142), (2017).
- Gabriele Nunes Souza, Nathália Kersting, Thomaz Abramsson Gonçalves, Daphne Louise Oliveira Pacheco, Maria-Luiza Saraiva-Pereira, Suzi Alves Camey, Jonas Alex Morales Saute and Laura Bannach Jardim, Cancer in Machado–Joseph disease patients—low frequency as a cause of death, Cancer Genetics, 212-213, (19), (2017).
- Filipe Brogueira Rodrigues, Daisy Abreu, Joana Damásio, Nilza Goncalves, Leonor Correia‐Guedes, Miguel Coelho and Joaquim J. Ferreira, Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort, Movement Disorders Clinical Practice, 4, 5, (737-742), (2017).
- Sebastian Aguiar, Bram van der Gaag and Francesco Albert Bosco Cortese, RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA, Translational Neurodegeneration, 6, 1, (2017).
- Morgane S. Thion and Sandrine Humbert, Au-delà du cerveau, médecine/sciences, 32, 8-9, (674), (2016).
- Jing Wu, Jun-ying Zhang, Li Yin, Jian-zhong Wu, Wen-jie Guo, Jian-feng Wu, Meng Chen, You-you Xia, Jin-hai Tang, Yong-chao Ma and Xia He, HAP1 gene expression is associated with radiosensitivity in breast cancer cells, Biochemical and Biophysical Research Communications, 456, 1, (162), (2015).
- Kiran Mall and Graham Ball, Interactomic Analysis of the Stem Cell Marker NANOG in a Prostate Cancer Setting, Principles of Stem Cell Biology and Cancer, (317-352), (2015).
- Shaun S. Sanders, Dale D. O. Martin, Stefanie L. Butland, Mathieu Lavallée-Adam, Diego Calzolari, Chris Kay, John R. Yates, Michael R. Hayden and Nir Ben-Tal, Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers, PLOS Computational Biology, 11, 8, (e1004405), (2015).
- Bernard J. Crespi and Matthew C. Go, Diametrical diseases reflect evolutionary-genetic tradeoffs, Evolution, Medicine, and Public Health, 10.1093/emph/eov021, 2015, 1, (216-253), (2015).
- Adriana Maria Kubis and Agnieszka Piwowar, The new insight on the regulatory role of the vitamin D3 in metabolic pathways characteristic for cancerogenesis and neurodegenerative diseases, Ageing Research Reviews, 24, (126), (2015).
- Ping Li, Yaling Nie, Jingkai Yu and Mark R. Cookson, An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases, PLOS ONE, 10, 11, (e0143045), (2015).
- Jane A. Driver, Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence, Biogerontology, 10.1007/s10522-014-9523-2, 15, 6, (547-557), (2014).
- M. Dhruba Singh, Kritika Raj and Surajit Sarkar, Drosophila Myc, a novel modifier suppresses the poly(Q) toxicity by modulating the level of CREB binding protein and histone acetylation, Neurobiology of Disease, 63, (48), (2014).
- Ferrán Catalá-López, Marta Suárez-Pinilla, Paula Suárez-Pinilla, Jose María Valderas, Manuel Gómez-Beneyto, Salvador Martinez, Vicent Balanzá-Martínez, Joan Climent, Alfonso Valencia, John McGrath, Benedicto Crespo-Facorro, Jose Sanchez-Moreno, Eduard Vieta and Rafael Tabarés-Seisdedos, Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies, Psychotherapy and Psychosomatics, 10.1159/000356498, 83, 2, (89-105), (2014).
- Richard A. Harris, Lauren Tindale and Robert C. Cumming, Age-dependent metabolic dysregulation in cancer and Alzheimer’s disease, Biogerontology, 10.1007/s10522-014-9534-z, 15, 6, (559-577), (2014).
- Dagmar E. Ehrnhoefer, Niels H. Skotte, Safia Ladha, Yen T.N. Nguyen, Xiaofan Qiu, Yu Deng, Khuong T. Huynh, Sabine Engemann, Signe M. Nielsen, Kristina Becanovic, Blair R. Leavitt, Lis Hasholt and Michael R. Hayden, p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin, Human Molecular Genetics, 10.1093/hmg/ddt458, 23, 3, (717-729), (2013).
- Cristovão Moreira Sousa, John Russel McGuire, Morgane Sonia Thion, David Gentien, Pierre de la Grange, Sophie Tezenas du Montcel, Anne Vincent‐Salomon, Alexandra Durr and Sandrine Humbert, The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling, EMBO Molecular Medicine, 5, 2, (309-325), (2013).
- LIWEI ZHU, XUE SONG, JINHAI TANG, JIANZHONG WU, RONG MA, HAIXIA CAO, MINGHUA JI, CHANGWEN JING and ZHUO WANG, Huntingtin-associated protein 1: A potential biomarker of breast cancer, Oncology Reports, 29, 5, (1881), (2013).
- MR Turner, R Goldacre and MJ Goldacre, Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary trade‐off?, Clinical Genetics, 83, 6, (588-590), (2012).
- Vibeke Sørensen Catts, Stanley Victor Catts, Assen Jablensky, David Chandler, Cynthia Shannon Weickert and Martin F. Lavin, Evidence of aberrant DNA damage response signalling but normal rates of DNA repair in dividing lymphoblasts from patients with schizophrenia, The World Journal of Biological Psychiatry, 13, 2, (114), (2012).
- S.Y. Cong, B.A. Pepers, T.T. Zhou, H. Kerkdijk, R.A. Roos, G.J. van Ommen and J.C. Dorsman, Huntingtin with an expanded polyglutamine repeat affects the Jab1-p27(Kip1) pathway, Neurobiology of Disease, 46, 3, (673), (2012).
- Jianguang Ji, Kristina Sundquist and Jan Sundquist, Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden, The Lancet Oncology, 13, 6, (642), (2012).
- Mahmoud A Pouladi and Michael R Hayden, Polyglutamine diseases and the risk of cancer, The Lancet Oncology, 13, 6, (569), (2012).
- Mónica Alejandra Rosales-Reynoso, Alejandra Berenice Ochoa-Hernández, Adriana Aguilar-Lemarroy, Luis Felipe Jave-Suárez, Rogelio Troyo-Sanromán and Patricio Barros-Núñez, Gene Expression Profiling Identifies WNT7A As a Possible Candidate Gene for Decreased Cancer Risk in Fragile X Syndrome Patients, Archives of Medical Research, 41, 2, (110), (2010).
- Adrien Daigeler, Ansgar M. Chromik, Kathrin Haendschke, Sabine Emmelmann, Monica Siepmann, Karin Hensel, Georg Schmitz, Ludger Klein-Hitpass, Hans U. Steinau, Marcus Lehnhardt and Joerg Hauser, Synergistic Effects of Sonoporation and Taurolidin/TRAIL on Apoptosis in Human Fibrosarcoma, Ultrasound in Medicine & Biology, 10.1016/j.ultrasmedbio.2010.08.009, 36, 11, (1893-1906), (2010).
- María I Behrens, Catherine M Roe, Andrew FG Quest and John C Morris, Is there a link between dementia and cancer?, Aging Health, 6, 3, (361), (2010).
- Roger L. Albin, Comment on Eskenazi et al., Medical Hypotheses, 71, 1, (151), (2008).
- Manolis Markianos, Marios Panas, Nikolaos Kalfakis and Demetrios Vassilopoulos, Low plasma total cholesterol in patients with Huntington’s disease and first-degree relatives, Molecular Genetics and Metabolism, 93, 3, (341), (2008).
- Francis O Walker, Huntington's disease, The Lancet, 369, 9557, (218), (2007).
- Benjamin R. Eskenazi, Noah S. Wilson-Rich and Philip T. Starks, A Darwinian approach to Huntington’s disease: Subtle health benefits of a neurological disorder, Medical Hypotheses, 69, 6, (1183), (2007).
- E Imyanitov, K Hanson and B Zhivotovsky, Polymorphic variations in apoptotic genes and cancer predisposition, Cell Death and Differentiation, 12, 8, (1004), (2005).
- Byoung-Il Bae, Hong Xu, Shuichi Igarashi, Masahiro Fujimuro, Nishant Agrawal, Yoichi Taya, S. Diane Hayward, Timothy H. Moran, Craig Montell, Christopher A. Ross, Solomon H. Snyder and Akira Sawa, p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease, Neuron, 47, 1, (29), (2005).
- Teresa S. Hyun and Theodora S. Ross, HIP1: trafficking roles and regulation of tumorigenesis, Trends in Molecular Medicine, 10, 4, (194), (2004).
- Miriam A. Hickey and Marie-Françoise Chesselet, Apoptosis in Huntington's disease, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10.1016/S0278-5846(03)00021-6, 27, 2, (255-265), (2003).
- Dinesh S. Rao, Teresa S. Hyun, Priti D. Kumar, Ikuko F. Mizukami, Mark A. Rubin, Peter C. Lucas, Martin G. Sanda and Theodora S. Ross, Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival, Journal of Clinical Investigation, 110, 3, (351), (2002).
- Søren Schultz‐Pedersen, Henrik Hasle, Jørgen H. Olsen and Ursula Friedrich, Evidence of decreased risk of cancer in individuals with fragile X, American Journal of Medical Genetics, 103, 3, (226-230), (2001).
- Henrik Hasle, Pattern of malignant disorders in individuals with Down's syndrome, The Lancet Oncology, 2, 7, (429), (2001).
- J. S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.-Z. Zhu, H. Gohler, E. E. Wanker, G. P. Bates, D. E. Housman and L. M. Thompson, The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription, Proceedings of the National Academy of Sciences, 97, 12, (6763), (2000).
- J. J. Mulvihill, Genes Protecting Against Cancers and Tumor Suppressor Genes, Genes and Resistance to Disease, 10.1007/978-3-642-56947-0_15, (169-178), (2000).
- Rafael Tabarés-Seisdedos and John L. Rubenstein, Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders, Nature Reviews Neuroscience, 10.1038/nrn3464, 14, 4, (293-304), (2013).
- Andrew M. Tidball, M. Diana Neely, Reed Chamberlin, Asad A. Aboud, Kevin K. Kumar, Bingying Han, Miles R. Bryan, Michael Aschner, Kevin C. Ess, Aaron B. Bowman and Atsushi Asakura, Genomic Instability Associated with p53 Knockdown in the Generation of Huntington’s Disease Human Induced Pluripotent Stem Cells, PLOS ONE, 10.1371/journal.pone.0150372, 11, 3, (e0150372), (2016).
- Hélène Plun-Favreau, Patrick A. Lewis, John Hardy, L. Miguel Martins, Nicholas W. Wood and Marshall S. Horwitz, Cancer and Neurodegeneration: Between the Devil and the Deep Blue Sea, PLoS Genetics, 10.1371/journal.pgen.1001257, 6, 12, (e1001257), (2010).
